Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer
Talia Golan, Alex Barenboim, Guy Lahat, Ido Nachmany, Yacov Goykhman, Einat Shacham‐Shmueli, Naama Halpern, Eli Brazowski, Ravit Geva, Ido Wolf, Yuri Goldes, Menahem Ben‐Haim, Joseph M. Klausner, Nir Lubezky
Topics & Concepts
FOLFIRINOXMedicineBRCA mutationNeoadjuvant therapySurgical oncologyGermline mutationPancreatic cancerInternal medicineOncologyPancreatectomyMutationCancerOxaliplatinPancreasBreast cancerColorectal cancerChemistryGeneBiochemistryPancreatic and Hepatic Oncology ResearchCancer Research and TreatmentsPARP inhibition in cancer therapy